Author:
Do Tran,Medhekar Rohan,Bhat Raksha,Chen Hua,Niravath Polly,Trivedi Meghana V.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. O’Shaughnessy JA (2007) Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer. Clin Breast Cancer 8(Suppl 1):S11–S21
2. Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M (2012) Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 10:CD007913. doi: 10.1002/14651858.CD007913.pub2
3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266. doi: 10.1002/cncr.21847
4. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26(4):606–611. doi: 10.1200/JCO.2007.13.8222
5. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8(6):963–977
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献